Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
balapiravir · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| balapiravir [RO4588161] | DRUG | sequential cohorts receiving doses orally twice daily for 5 days |
| placebo | DRUG | orally twice daily for 5 days |
Inclusion Criteria: * male patients, 18-65 years of age * dengue virus infection (confirmed by NS1 strip test) with symptom onset \</=48 hours before first study drug administration * patients and their partners of childbearing potential must use 2 forms of contraception until 3 months after receiv...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 5 | PHASE3 | Tetravalent Dengue Vaccine |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | EYU688 |
| Sanofi SA Sponsored ADR | SNY | 1 | - | Undisclosed |
| Abbott Laboratories | ABT | 1 | - | Undisclosed |
| Danaher Corporation | DHR | 1 | - | Undisclosed |
Balapiravir is an investigational small molecule being studied for the treatment of dengue virus infection. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated in patients with dengue, a mosquito-borne viral illness.
Balapiravir is being developed by Roche Holding AG, a multinational pharmaceutical company. Roche's stock is traded under the ticker symbol RHHBY on the OTC market. The company is conducting clinical research on this investigational drug for dengue virus infection.
Balapiravir is in Phase 1 clinical development. It is an investigational drug and has not received regulatory approval. A Phase 1 study of balapiravir in patients with dengue virus infection has been completed, but the drug remains in early-stage clinical testing.
Balapiravir has one completed clinical trial registered as NCT01096576, titled 'A Study of Balapiravir in Patients With Dengue Virus Infection.' This Phase 1 study enrolled 64 male participants aged 18 years and older in Vietnam. The trial was placebo-controlled and double-blind, but was not randomized.
Balapiravir is not known to have alternative names. It is a distinct investigational small molecule being developed by Roche for dengue virus infection. No other names for this drug have been reported in clinical trial registrations.